| __timestamp | Alkermes plc | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 68205000 |
| Thursday, January 1, 2015 | 4019000 | 54218000 |
| Friday, January 1, 2016 | 2301000 | 15934000 |
| Sunday, January 1, 2017 | 7232000 | 24390000 |
| Monday, January 1, 2018 | 68895000 | 25389000 |
| Tuesday, January 1, 2019 | 52816000 | 72324000 |
| Wednesday, January 1, 2020 | 1946000 | 184809000 |
| Friday, January 1, 2021 | 1020000 | 205164000 |
| Saturday, January 1, 2022 | 393842000 | 245441000 |
| Sunday, January 1, 2023 | 270806000 | 271823000 |
| Monday, January 1, 2024 | 245326000 |
Igniting the spark of knowledge
In the competitive world of biopharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Madrigal Pharmaceuticals, Inc. and Alkermes plc have shown contrasting trends in their R&D investments. From 2014 to 2023, Madrigal Pharmaceuticals increased its R&D spending by approximately 300%, peaking in 2023 with a 270% rise compared to 2014. This surge underscores Madrigal's aggressive pursuit of groundbreaking therapies.
Conversely, Alkermes plc exhibited a more volatile R&D expenditure pattern. Despite a significant spike in 2022, where spending soared by over 500% from 2014, the company's investment fluctuated, reflecting strategic shifts in its research focus. By 2023, Alkermes' R&D spending was nearly on par with Madrigal's, highlighting a renewed commitment to innovation. These trends offer a fascinating glimpse into the strategic priorities of these industry leaders.
Comparing Innovation Spending: Novartis AG and Alkermes plc
Research and Development Expenses Breakdown: Amgen Inc. vs Madrigal Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Alkermes plc
R&D Insights: How Genmab A/S and Madrigal Pharmaceuticals, Inc. Allocate Funds
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
Incyte Corporation or Madrigal Pharmaceuticals, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc.
Research and Development Investment: Pharming Group N.V. vs Alkermes plc
Who Prioritizes Innovation? R&D Spending Compared for Madrigal Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc.
R&D Spending Showdown: Madrigal Pharmaceuticals, Inc. vs Galapagos NV
Research and Development Investment: Corcept Therapeutics Incorporated vs Alkermes plc
Research and Development Investment: Alkermes plc vs ADMA Biologics, Inc.